JP2011519941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519941A5 JP2011519941A5 JP2011508584A JP2011508584A JP2011519941A5 JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5 JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- formula
- cancer
- erbb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- -1 morpholino, piperidinyl Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC Chemical compound COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032208P | 2008-05-05 | 2008-05-05 | |
| US61/050,322 | 2008-05-05 | ||
| PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519941A JP2011519941A (ja) | 2011-07-14 |
| JP2011519941A5 true JP2011519941A5 (https=) | 2012-06-21 |
Family
ID=41257222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508584A Pending JP2011519941A (ja) | 2008-05-05 | 2009-05-05 | ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090274693A1 (https=) |
| EP (1) | EP2274304A4 (https=) |
| JP (1) | JP2011519941A (https=) |
| KR (1) | KR20110004462A (https=) |
| CN (1) | CN102083824A (https=) |
| AR (1) | AR071631A1 (https=) |
| AU (1) | AU2009244453B2 (https=) |
| BR (1) | BRPI0912582A2 (https=) |
| CA (1) | CA2723699A1 (https=) |
| CL (1) | CL2009001063A1 (https=) |
| EA (1) | EA020779B1 (https=) |
| IL (1) | IL209057A0 (https=) |
| MX (1) | MX2010012101A (https=) |
| PE (1) | PE20091832A1 (https=) |
| SG (1) | SG190623A1 (https=) |
| TW (1) | TW201006829A (https=) |
| UY (1) | UY31800A (https=) |
| WO (1) | WO2009137429A1 (https=) |
| ZA (1) | ZA201007722B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| MA33208B1 (fr) | 2009-03-25 | 2012-04-02 | Genentech Inc | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci |
| PT2451445T (pt) | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo |
| TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP2896632B1 (en) * | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| AU2011290672B2 (en) | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| MX352926B (es) | 2010-09-27 | 2017-12-14 | Exelixis Inc | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
| SG191230A1 (en) * | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| MX2013012695A (es) * | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| SG11201402004YA (en) * | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| EP3590538A1 (en) * | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| BR112016008125B1 (pt) | 2013-10-14 | 2023-11-21 | Janssen Biotech, Inc. | Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína |
| US11045468B2 (en) | 2014-02-04 | 2021-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| EP3125935B1 (en) | 2014-04-03 | 2019-10-23 | Merck Patent GmbH | Combinations of cancer therapeutics |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| MX382904B (es) | 2014-08-05 | 2025-03-13 | Exelixis Inc | Combinaciones de fármacos para tratar mieloma múltiple. |
| ES2749726T3 (es) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Derivado de quinolina |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| MA45412A (fr) | 2016-06-21 | 2021-05-26 | Janssen Biotech Inc | Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| TWI779007B (zh) | 2017-01-26 | 2022-10-01 | 日商小野藥品工業股份有限公司 | 喹啉衍生物的乙磺酸鹽 |
| WO2018151177A1 (ja) | 2017-02-15 | 2018-08-23 | 大鵬薬品工業株式会社 | 医薬組成物 |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| BR112021014504A2 (pt) * | 2019-01-25 | 2021-09-28 | Exelixis, Inc. | Compostos para o tratamento de transtornos dependentes de cinase |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| EP4323008A4 (en) | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| EP1962903B1 (en) * | 2005-12-15 | 2013-03-13 | MedImmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
| PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| KR101523788B1 (ko) * | 2007-05-17 | 2015-06-26 | 제넨테크, 인크. | 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조 |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en not_active Ceased
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Ceased
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519941A5 (https=) | ||
| JP2021523159A5 (https=) | ||
| JP2023542066A5 (https=) | ||
| AR071631A1 (es) | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres | |
| RU2013143381A (ru) | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и ее медицинское применение | |
| JP6557744B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2012504628A5 (https=) | ||
| RU2018103454A (ru) | Соединения бензоксазепиноксазолидинонов и способы применения | |
| JP2018504418A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2014528433A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2014533284A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2014518544A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2013520431A5 (https=) | ||
| JP2011516610A5 (https=) | ||
| RU2012139825A (ru) | Антагонисты неурегулина и применение их в лечении злокачественного новообразования | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2012520321A5 (https=) | ||
| JP2020534300A5 (https=) | ||
| JP2014502599A5 (https=) |